TABLE 4.
Similar and different predicted targets of different top “canonical pathways” and “disease and functions” categories related to cancer.
| miRNA impacted by aging | Target | FC/ targets | Molecular mechanisms of cancer | Glioblastoma multiforme signaling | Endocannabinoid cancer inhibition pathway | Glioma signaling | Digestive system cancer | Endocrine gland tumor | Type(s) |
|---|---|---|---|---|---|---|---|---|---|
| miR-15b-5p | AKT serine/threonine kinase 3 | −1.37 | AKT3 | AKT3 | AKT3 | AKT3 | AKT3 | AKT3 | Kinase |
| miR-24-3p | Rho guanine nucleotide exchange factor | ||||||||
| 15 | -1.324 | ARHGEF15 | ARHGEF15 | ARHGEF1 5 | Other | ||||
| miR-24-3p and miR-27a-3p | BCL2-associated X, apoptosis regulator | −1.324 and −1.256 | BAX | BAX | BAX | Transporter | |||
| miR-24-3p and miR-27a-3p | BCL2 binding component 3 | −1.324 and −1.256 | BBC3 | BBC3 | Other | ||||
| miR-15b-5p and miR-448-3p | BCL2 apoptosis regulator | −1.37 and 1.256 | BCL2 | BCL2 | BCL2 | Transporter | |||
| miR-24-3p and miR-92b-3p | BCL2-like 11 | −1.324 and −1.208 | BCL2L11 | BCL2L11 | BCL2L11 | Other | |||
| miR-92b-3p | Bone morphogenetic protein receptor type 2 | −1.208 | BMPR2 | BMPR2 | BMPR2 | Kinase | |||
| miR-503-3p | B-Raf proto-oncogene, serine/threonine kinase | −1.381 | BRAF | BRAF | BRAF | Kinase | |||
| miR-24-3p | BRCA1 DNA repair associated | −1.324 | BRCA1 | BRCA1 | BRCA1 | Transcription regulator | |||
| miR-15b-5p | Cyclin D1 | −1.37 | CCND1 | CCND1 | CCND1 | CCND1 | CCND1 | CCND1 | Transcription regulator |
| miR-15b-5p | Cyclin E1 | −1.37 | CCNE1 | CCNE1 | CCNE1 | CCNE1 | CCNE1 | Transcription regulator | |
| miR-15b-5p | Cell division cycle 25A | −1.37 | CDC25A | CDC25A | Phosphatase | ||||
| miR-24-3p | Cyclin-dependent kinase 1 | −1.324 | CDK1 | CDK1 | CDK1 | Kinase | |||
| miR-15b-5p | Cyclin-dependent kinase 17 | −1.37 | CDK17 | CDK17 | CDK17 | Kinase | |||
| miR-24-3p | Cyclin-dependent kinase 4 | −1.324 | CDK4 | CDK4 | CDK4 | CDK4 | CDK4 | Kinase | |
| miR-15b-5p | Cyclin-dependent kinase 6 | −1.37 | CDK6 | CDK6 | CDK6 | CDK6 | CDK6 | Kinase | |
| miR-15b-5p | Cyclin-dependent kinase 8 | −1.37 | CDK8 | CDK8 | CDK8 | Kinase | |||
| miR-92b-3p | Cyclin-dependent kinase inhibitor 1A | −1.208 | CDKN1A | CDKN1A | CDKN1A | CDKN1A | CDKN1A | CDKN1A | Kinase |
| miR-24-3p | Cyclin-dependent kinase inhibitor 1B | −1.324 | CDKN1B | CDKN1B | CDKN1B | CDKN1B | CDKN1B | Kinase | |
| miR-24-3p | Cyclin-dependent kinase inhibitor 2A | −1.324 | CDKN2A | CDKN2A | CDKN2A | CDKN2A | CDKN2A | Transcription regulator | |
| miR-15b-5p | Checkpoint kinase 1 | −1.37 | CHEK1 | CHEK1 | CHEK1 | Kinase | |||
| miR-24-3p | E2F transcription factor 2 | −1.324 | E2F2 | E2F2 | E2F2 | E2F2 | E2F2 | Transcription regulator | |
| miR-15b-5p | E2F transcription factor 3 | −1.37 | E2F3 | E2F3 | E2F3 | E2F3 | E2F3 | Transcription regulator | |
| miR-15b-5p | E2F transcription factor 7 | −1.37 | E2F7 | E2F7 | E2F7 | E2F7 | E2F7 | Transcription regulator | |
| miR-27a-3p | GRB2-associated binding protein 1 | −1.256 | GAB1 | GAB1 | GAB1 | Other | |||
| miR-15b-3p and miR-27a-3p | Growth factor receptor bound protein 2 | −1.37 and −1.324 | GRB2 | GRB2 | GRB2 | GRB2 | GRB2 | Other | |
| miR-15b-5p | Indian hedgehog signaling molecule | −1.37 | IHH | IHH | IHH | Enzyme | |||
| miR-15b-5p | Integrin subunit alpha 2 | −1.37 | ITGA2 | ITGA2 | ITGA2 | Transmembrane receptor | |||
| miR-92b-3p | Integrin subunit alpha 5 | −1.208 | ITGA5 | ITGA5 | ITGA5 | Transmembrane receptor | |||
| miR-15b-5p | Jun proto-oncogene, AP-1 transcription factor subunit | −1.37 | JUN | JUN | Transcription regulator | ||||
| miR-15b-5p | Late endosomal/lysoso mal adaptor, MAPK and MTOR activator 3 | −1.37 | LAMTOR3 | LAMTOR3 | Other | ||||
| miR-219a-5p | Lymphoid enhancer binding factor 1 | 1.521 | LEF1 | LEF1 | LEF1 | LEF1 | LEF1 | Transcription regulator | |
| miR-15b-5p | Mitogen-activated protein kinase 1 | −1.37 | MAP2K1 | MAP2K1 | MAP2K1 | MAP2K1 | MAP2K1 | MAP2K1 | Kinase |
| miR-15b-5p, miR-24-3p, miR-92b-3p and miR-27a-3p | Mitogen-activated protein kinase 4 | −1.37, −1.324, −1.208 and −1.256 | MAP2K4 | MAP2K4 | MAP2K4 | MAP2K4 | Kinase | ||
| miR-15b-5p | Mitogen-activated protein kinase 3 | −1.37 | MAPK3 | MAPK3 | MAPK3 | MAPK3 | MAPK3 | MAPK3 | Kinase |
| miR-24-3p and miR-377-5p | MYC proto-oncogene, bHLH | −1.324 and −1.308 | MYC | MYC | MYC | MYC | MYC | Transcription regulator | |
| Transcription factor | |||||||||
| miR-24-3p and miR-27a-3p | Notch receptor 1 | −1.324 and −1.256 | NOTCH1 | NOTCH1 | NOTCH1 | Transcription regulator | |||
| miR-219a-5p | Phosphatidylinosit ol-4-phosphate 3-kinase catalytic subunit type 2 gamma | 1.521 | PIK3C2G | PIK3C2G | PIK3C2G | PIK3C2G | PIK3C2G | PIK3C2G | Kinase |
| miR-92b-3p | Phosphoinositide-3-kinase regulatory subunit 3 | −1.208 | PIK3R3 | PIK3R3 | PIK3R3 | PIK3R3 | PIK3R3 | Kinase | |
| miR-24-3p, miR-377-5p and miR-448-3p | Phorbol-12-myristate-13-acetate-induced protein 1 | −1.324, −1.308 and 1.256 | PMAIP1 | PMAIP1 | Other | ||||
| miR-15b-5p | Raf-1 proto-oncogene, serine/threonine kinase | −1.37 | RAF1 | RAF1 | RAF1 | RAF1 | RAF1 | RAF1 | Kinase |
| miR-24-3p | RAP1A, member of RAS oncogenefamily | −1.324 | RAP1A | RAP1A | RAP1A | RAP1A | RAP1A | Enzyme | |
| miR-24-3p | RAP1B, member of RAS oncogenefamily | −1.324 | RAP1B | RAP1B | RAP1B | RAP1B | Enzyme | ||
| miR-377-5p | RAS p21 protein activator 1 | −1.308 | RASA1 | RASA1 | RASA1 | Transporter | |||
| miR-24-3p | RAS p21 protein activator 2 | −1.324 | RASD2 | RASD2 | RASD2 | RASD2 | Enzyme | ||
| miR-24-3p and miR-27a-3p | SMAD family member 4 | −1.324 and −1.256 | SMAD4 | SMAD4 | SMAD4 | Transcription regulator | |||
| miR-24-3p and miR-27a-3p | SMAD family member 5 | −1.324 and −1.256 | SMAD5 | SMAD5 | Transcription regulator | ||||
| miR-15b-5p | SMAD family member 7 | −1.37 | SMAD7 | SMAD7 | SMAD7 | Transcription regulator | |||
| miR-27a-3p | SMAD family member 9 | −1.256 | SMAD9 | SMAD9 | Transcription regulator |
Molecular mechanisms of cancer had z= #num. Glioblastoma multiforme signaling, endocannabinoid cancer inhibition pathway, and glioma signaling, showed negative z-score, compared with those that IPA indicated positive z-score, digestive system cancer, and endocrine organ tumor.